期刊文献+

万古霉素相关肾毒性的主动监测研究 被引量:13

The active surveillance of vancomycin-related nephrotoxicity
下载PDF
导出
摘要 目的:研究应用计算机辅助系统实现主动监测住院患者万古霉素肾毒性的可行性和关键要素。方法:基于住院患者药品不良事件主动监测与评估警示系统,通过团队论证的方式设定住院患者万古霉素肾毒性主动监测的事件配置器,回顾性调取2012年10月1日–2013年8月27日我院经静脉途径应用万古霉素的住院患者,对系统提示的阳性预警病例进行人工再评价。结果:实际共筛查病例619例次,系统提示的阳性预警病例为9例次,经人工再评价的实际阳性病例为4例次,阳性预警率为0.65%。结论:住院患者药品不良事件主动监测与评估警示系统对万古霉素肾毒性的阳性预警率与文献报道结果相符,应用系统进行主动监测研究中事件配置器的参数设置为关键要素,应基于不同目标药物和药品不良事件特点进行个体化设置。 Objective: To study the feasibility and key elements of active surveillance of vancomycin-related nephrotoxicityin hospitalized patients based on computer-aided system. Methods: Based on inpatient's active monitor and assessment system ofadverse drug events and the event monitor configurator of vancomycin-related nephrotoxicity set by team work, the retrospectivemethod was used for evaluating the hospitalized patients of PLA General Hospital from October 1, 2012 to August 27, 2013 whointravenously used the vancomycin. The positive warning cases were manually re-evaluated. Results: Among 619 actual screeningcases, there were 9 warning cases auto screened by the system. After manual re-evaluation, the actual positive cases were 4 cases, thepositive warning rate was 0.65%. Conclusion: The positive warning rate of vancomycin-related nephrotoxicity by inpatient's activemonitor and assessment system was consistent with that of the literature. Setting parameters of adverse drug events configurator inthis system was the key point and should be based on different target drugs as well as the different characteristics of adverse drug events.
出处 《中国药物应用与监测》 CAS 2014年第1期26-29,共4页 Chinese Journal of Drug Application and Monitoring
基金 军队十二五面上项目 军队药品风险防控关键技术研究(CWS12J127)
关键词 万古霉素 肾毒性 主动监测 药品不良事件 Vancomycin Nephrotoxicity Active surveillance Adverse drug events
  • 相关文献

参考文献7

二级参考文献36

共引文献726

同被引文献129

  • 1周娟华.老年慢性病人用药现状及进展[J].护理研究(下半月),2005,19(2):289-290. 被引量:2
  • 2王宗敏,吴晓明.英国处方事件监测制度研究[J].中国药房,2005,16(24):1891-1892. 被引量:4
  • 3许建明.急性药物性肝损伤诊治建议(草案)[J].中华消化杂志,2007,27(11):765-767. 被引量:349
  • 4Chen C,Guo DH,Cao XT,et al. Risk Factors for Thrombocy- topenia in Adult Chinese Patients Receiving Linezolid Therapy [ J ]. Current Therapeutic Research ,2012,12 (6) : 195-206.
  • 5Miller AB, Hoogstraten B, Staquet M, et al. Reporting re- suits of cancer treatment[J]. Cancer, 1981,47(1 ) : 207-214.
  • 6Massimo DM, Ciro G, Natasha B, et al. Symptomatic toxicities experienced during anticancer treatment:Agreement between patient and physician reporting in three randomized trials [ J]. Journal of Clinical Oncology, 2015,26 : 1-7.
  • 7Harpaz R, DuMouchel W, Shah NH, et al. Novel data-mining methodologies for adverse drug event discovery and analysis[J]. Clin Pharmacol Ther, 2012, 91(6): 1010-1021.
  • 8Overhage JM, Ryan PB, Reich CG, et al. Validation of a common data model for active safety surveillance research[J]. J Am Med Inform Assoc, 2012, 19(1): 54-60.
  • 9Madigan D, Ryan PB, Schuemie M, et al. Evaluating the impact of database heterogeneity on observational study results[J]. Am J Epidemiol, 2013, 178(4): 645-651.
  • 10Hansen RA, Gray MD, Fox BI, et al. How well do various health outcome definitions identify appropriate cases in observational studies?[J]. Drug Saf, 2013, 36(Suppl 1): $27-$32.

引证文献13

二级引证文献139

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部